
## Lukas Carter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9502488/publications.pdf Version: 2024-02-01



LUKAS CADTED

#	Article	IF	CITATIONS
1	Multiplexed imaging for diagnosis and therapy. Nature Biomedical Engineering, 2017, 1, 697-713.	22.5	133
2	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature Communications, 2018, 9, 5137.	12.8	78
3	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology, 2020, 295, 606-615.	7.3	73
4	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2881.	7.0	69
5	Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. Theranostics, 2020, 10, 567-584.	10.0	63
6	Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 868-880.	7.0	55
7	PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	5.0	51
8	The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. Molecular Imaging and Biology, 2020, 22, 73-84.	2.6	50
9	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36
10	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	0.9	31
11	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of Nuclear Medicine, 2019, 60, 1569-1578.	5.0	27
12	PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms. Journal of Nuclear Medicine, 2019, 60, 1802-1811.	5.0	27
13	An <sup>89</sup> Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. Journal of Nuclear Medicine, 2020, 61, 433-436.	5.0	25
14	Preclinical optimization of antibodyâ€based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 611-635.	1.0	24
15	pHLIP ICG for delineation of tumors and blood flow during fluorescence-guided surgery. Scientific Reports, 2020, 10, 18356.	3.3	19
16	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clinical Cancer Research, 2022, 28, 1391-1401.	7.0	19
17	Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	17
18	Measurement of cesium diffusion coefficients in graphite IG-110. Journal of Nuclear Materials, 2015, 460, 30-36.	2.7	16

LUKAS CARTER

#	Article	IF	CITATIONS
19	Oncology-Inspired Treatment Options for COVID-19. Journal of Nuclear Medicine, 2020, 61, 1720-1723.	5.0	15
20	ICP-MS measurement of diffusion coefficients of Cs in NBG-18 graphite. Journal of Nuclear Materials, 2015, 466, 402-408.	2.7	11
21	PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes. Frontiers in Oncology, 2022, 12, .	2.8	11
22	Diffusion of cesium and iodine in compressed IC-110 graphite compacts. Journal of Nuclear Materials, 2016, 476, 30-35.	2.7	10
23	Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization. EJNMMI Research, 2020, 10, 49.	2.5	10
24	ICP-MS measurement of iodine diffusion in IG-110 graphite for HTGR/VHTR. Journal of Nuclear Materials, 2016, 473, 218-222.	2.7	9
25	Imaging of Cancer Î <sup>3</sup> -Secretase Activity Using an Inhibitor-Based PET Probe. Clinical Cancer Research, 2021, 27, 6145-6155.	7.0	8
26	ICP-MS measurement of silver diffusion coefficient in graphite IG-110 between 1048K and 1284K. Journal of Nuclear Materials, 2018, 498, 44-49.	2.7	7
27	CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773.	2.8	7
28	Patient Size-Dependent Dosimetry Methodology Applied to <sup>18</sup> F-FDG Using New ICRP Mesh Phantoms. Journal of Nuclear Medicine, 2021, 62, 1805-1814.	5.0	7
29	Calibration of a system for measurements of diffusion coefficients of fission products in HTGR/VHTR core materials. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 1771-1775.	1.5	6
30	lmaging Early-Stage Metastases Using an 18F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. Molecular Imaging and Biology, 2021, 23, 340-349.	2.6	6
31	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
32	Sorption of Ag and its vaporization from graphite at high temperatures. Journal of Nuclear Materials, 2017, 493, 132-146.	2.7	5
33	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	5.0	5
34	Personalized dosimetry of <sup>177</sup> Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomedical Physics and Engineering Express, 2021, 7, 057002.	1.2	4
35	3D-Printable Platform for High-Throughput Small-Animal Imaging. Journal of Nuclear Medicine, 2020, 61, 1691-1692.	5.0	3
36	Technical Note: Patientâ€norphed meshâ€ŧype phantoms to support personalized nuclear medicine dosimetry — a proof of concept study. Medical Physics, 2021, 48, 2018-2026.	3.0	2

#	Article	IF	CITATIONS
37	REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19. Journal of Nuclear Medicine, 2021, 62, jnumed.121.261950.	5.0	0
38	Metal-based Radiotherapeutics. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 271-307.	0.8	0